Acutaas Chemical Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹433Cr
- +40.6% YoY
- +10.2% QoQ
- Net profit
- ₹134Cr
- +112.7% YoY
- +26.4% QoQ
- Margin
- 42%
- +14 pp YoY
- +4 pp QoQ
Guidance rank: #17 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17). Revenue growth guidance for FY '27 is 25% CAGR, in line with the company’s history of over a decade.
From Acutaas Chemical's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17).
- Growth drivers for FY '27 and beyond include:
- Electrolyte additive division (battery chemicals).
- Pharma intermediate business, which is the biggest growth engine.
- Semiconductor chemical business, starting with BFC and Indichem JV in 2-3 years (Page 15).
- CDMO business has a long-term 10-year contract ensuring visibility and revenue stability; with multiple new products in validation/commercial phases (Page 14-15).
- Electrolyte additive capacity expansion underway; capacity of 2,000 MT indicates significant revenue potential (Page 14).
- Seasonality effect expected but new contracts like Fermion ramp-up may reduce Q1 dips (Page 17).
2 more points from Acutaas Chemical's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Acutaas Chemical said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '26 capex was INR195 crores focused on Jhagadia site for battery chemical project and pilot plant at Sachin site, plus maintenance.
- Spillover capex of around INR50 crores related to electrolyte additive and pilot plant expected in FY '27.
- FY '27 planned capex around INR90 crores (INR50 crores spillover + INR40 crores maintenance), excluding new R&D center costs.
- New versatile R&D center planned with ~10x capacity expansion, covering pharmaceuticals, battery chemicals, semiconductors, electronics, cosmetics, and more.
- Continued investment in the South Korea joint venture Indichem with INR190 crores invested in FY '26; plant commissioning expected in second half of calendar 2026.
2 more points from Acutaas Chemical's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Acutaas Chemical said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- For the CDMO business, Acutaas Chemicals has a confirmed long-term supply contract in place for 10 years with their first customer, providing good visibility and backlog.
- The electrolyte additive segment has customer contracts already signed, covering the full 2,000 metric ton capacity for at least the next 3 years.
- There are four additional CDMO products beyond the Fermion contract, validated and awaiting regulatory approval, with each expected to have a revenue potential of INR 50-100 crores at peak levels.
2 more points from Acutaas Chemical's call on order book
Create a free account to keep reading this call
Acutaas Chemical — Quarterly revenue & net profit
Acutaas Chemical Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 433 | 308 | +40.6% | 393 | +10.2% |
| Operating profit (EBITDA) | 184 | 85 | +116.5% | 151 | +21.9% |
| Operating margin | 42% | 28% | +14 pp | 38% | +4 pp |
| Profit before tax | 184 | 83 | +121.7% | 145 | +26.9% |
| Net profit (PAT) | 134 | 63 | +112.7% | 106 | +26.4% |
| EPS (₹) | 16.09 | 7.63 | +110.9% | 13.19 | +22% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹437 Cr, net profit ₹123 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Acutaas Chemical's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Acutaas Chemical and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Acutaas Chemical Q4 FY26 results?
The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17). Revenue growth guidance for FY '27 is 25% CAGR, in line with the company’s history of over a decade.
What is Acutaas Chemical share price analysis?
Acutaas Chemical currently shows a neutral. The stock trades at a P/E of 67.2 with a market cap of ₹25,945 Cr. Investors should review the full earnings analysis for detailed insights.
Is Acutaas Chemical planning capital expenditure?
FY '26 capex was INR195 crores focused on Jhagadia site for battery chemical project and pilot plant at Sachin site, plus maintenance.
Keep Acutaas Chemical on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
